SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 6)
MedQuist Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)
584949101
--------------------------------------------------------------------------------
(CUSIP Number)
Neil T. Anderson, Esq.
Sullivan & Cromwell LLP
125 Broad Street
New York, New York 10004-2498
(212) 558-4000
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
November 8, 2007
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If a filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d- 1(g), check
the following box [ ].
--------------------------------------------------------------------------------
CUSIP NO. 584949101
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON
Koninklijke Philips Electronics N.V.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
222531298
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. SOURCE OF FUNDS
OO
--------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)
[_]
--------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
The Netherlands
--------------------------------------------------------------------------------
7. SOLE VOTING POWER
NUMBER OF 26,085,086
SHARES --------------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------------
REPORTING 9. SOLE DISPOSITIVE POWER
PERSON 26,085,086
WITH --------------------------------------------------------------
10. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
26,085,086
--------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
[_]
--------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
69.6%
--------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
-2-
Item 1. Security and Issuer.
This Amendment No. 6 relates to the common stock, no par value (the
"Shares") of MedQuist Inc., a New Jersey corporation ("MedQuist"). This
Amendment No. 6 amends and supplements Item 6 and Item 7 of the Statement on
Schedule 13D dated June 6, 2000 (the "Schedule 13D") filed by Koninklijke
Philips Electronics N.V., a corporation incorporated under the laws of The
Netherlands ("Philips"), as previously amended and supplemented by Amendment No.
1 to the Schedule 13D, dated July 28, 2000, Amendment No. 2 to the Schedule 13D,
dated August 2, 2000, Amendment No. 3 to the Schedule 13D, dated August 24,
2000, Amendment No. 4 to the Schedule 13D, dated July 6, 2007 and Amendment No.
5 to the Schedule 13D, dated November 2, 2007. Unless otherwise defined herein,
all capitalized terms used herein shall have the meanings ascribed to them in
the Schedule 13D.
Item 6. Contracts, Arrangements, Understandings
or Relationships with Respect to
Securities of the Issuer.
On November 8, 2007, MedQuist and Philips entered into an amendment
(the "Amendment") of the Governance Agreement by and between MedQuist and
Philips dated May 22, 2000 (the "Governance Agreement"). The Supervisory
Committee of the Board of Directors of MedQuist (the "Board"), responsible for,
among other things, the general oversight, administration, amendment and
enforcement of all material agreements or arrangements between MedQuist and
Philips, approved the Amendment.
The Amendment establishes the composition of the Board in the event the
number of directors constituting the whole Board is set at seven (its current
size). It also provides for vacancies in Board seats held by Independent
Directors (as defined in the Governance Agreement) to be filled by an
affirmative vote of the remaining directors in the event there are no
Independent Directors on the Board.
A complete copy of the Amendment is attached to this report as
Exhibit 1 and is incorporated herein by reference.
Item 7. Material to be Filed as Exhibits
Exhibit Description
------- -----------
1 Amendment, dated November 8, 2007, to the Governance
Agreement, dated May 22, 2000, between Philips and
MedQuist.
-3-
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: November 13, 2007
KONINKLIJKE PHILIPS ELECTRONICS N.V.
By: /s/ P.J. SIVIGNON
----------------------------------------
Name: P.J. Sivignon
Title: Executive Vice President & CFO
By: /s/ E.P. COUTINHO
----------------------------------------
Name: E.P. Coutinho
Title: General Secretary
and Chief Legal Officer
-4-